Cargando…

First report of tamoxifen‐induced baboon syndrome

BACKGROUND: Baboon syndrome is a rare, type IV hypersensitivity reaction causing a maculopapular rash. Tamoxifen is an antineoplastic agent, working as an estrogen receptor antagonist, also called a selective estrogen receptor modulator. A variety of rashes were reported with Tamoxifen use to‐date e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mofarrah, Ramin, Mofarrah, Ramina, Kränke, Birger, Rahmani, Maziar, Jahani Amiri, Kousar, Ghasemi, Maryam, Jallab, Naghmeh, Ghobadiaski, Sueshianth, Rahmani, Nazgol, Hashemi, Narges
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451808/
https://www.ncbi.nlm.nih.gov/pubmed/33253493
http://dx.doi.org/10.1111/jocd.13863
_version_ 1784569928271003648
author Mofarrah, Ramin
Mofarrah, Ramina
Kränke, Birger
Rahmani, Maziar
Jahani Amiri, Kousar
Ghasemi, Maryam
Jallab, Naghmeh
Ghobadiaski, Sueshianth
Rahmani, Nazgol
Hashemi, Narges
author_facet Mofarrah, Ramin
Mofarrah, Ramina
Kränke, Birger
Rahmani, Maziar
Jahani Amiri, Kousar
Ghasemi, Maryam
Jallab, Naghmeh
Ghobadiaski, Sueshianth
Rahmani, Nazgol
Hashemi, Narges
author_sort Mofarrah, Ramin
collection PubMed
description BACKGROUND: Baboon syndrome is a rare, type IV hypersensitivity reaction causing a maculopapular rash. Tamoxifen is an antineoplastic agent, working as an estrogen receptor antagonist, also called a selective estrogen receptor modulator. A variety of rashes were reported with Tamoxifen use to‐date except baboon syndrome. The Tamoxifen‐induced baboon syndrome seems to be reversible, as discontinuation of the drug improves clinical outcomes. AIM: Herein, we present the first case of Tamoxifen‐induced baboon syndrome which occurred 8 years after initiation of Tamoxifen use. PATIENTS: A 44‐year‐old woman presented with papulovesicular eruption on her body and erythema on her face for a duration of 6 months. There was no evidence of ocular or mucosal involvement. She was diagnosed with breast cancer and treated with tamoxifen 10 mg twice daily over the past 8 years. She was not taking other medications or over‐the‐counter supplements at the time of presentation. The patient underwent urgent skin biopsies of two lesions on her buttock and thigh. No organisms were seen on Gram stain. The patient's skin biopsy revealed extensive hyperorthokeratosis, minimal parakeratosis, hypergranulosis, and lichenoid interface dermatitis in the irregularly acanthotic epidermis supporting diagnosis of fixed drug eruption. Following a multidisciplinary discussion, the patient was diagnosed with baboon syndrome or symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) associated with Tamoxifen. RESULTS: Hence, Tamoxifen was immediately discontinued and treated with oral steroid along with topical agents. She showed improvement of clinical abnormalities within days after discontinuation of Tamoxifen. CONCLUSIONS: Given the widespread use of Tamoxifen in the management of patients with breast cancer, it is important that healthcare professionals monitor for rare, however clinically significant, and potentially life‐threatening dermatological manifestations of Tamoxifen use, such as baboon syndrome.
format Online
Article
Text
id pubmed-8451808
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84518082021-09-27 First report of tamoxifen‐induced baboon syndrome Mofarrah, Ramin Mofarrah, Ramina Kränke, Birger Rahmani, Maziar Jahani Amiri, Kousar Ghasemi, Maryam Jallab, Naghmeh Ghobadiaski, Sueshianth Rahmani, Nazgol Hashemi, Narges J Cosmet Dermatol Dermatologic Surgery Articles BACKGROUND: Baboon syndrome is a rare, type IV hypersensitivity reaction causing a maculopapular rash. Tamoxifen is an antineoplastic agent, working as an estrogen receptor antagonist, also called a selective estrogen receptor modulator. A variety of rashes were reported with Tamoxifen use to‐date except baboon syndrome. The Tamoxifen‐induced baboon syndrome seems to be reversible, as discontinuation of the drug improves clinical outcomes. AIM: Herein, we present the first case of Tamoxifen‐induced baboon syndrome which occurred 8 years after initiation of Tamoxifen use. PATIENTS: A 44‐year‐old woman presented with papulovesicular eruption on her body and erythema on her face for a duration of 6 months. There was no evidence of ocular or mucosal involvement. She was diagnosed with breast cancer and treated with tamoxifen 10 mg twice daily over the past 8 years. She was not taking other medications or over‐the‐counter supplements at the time of presentation. The patient underwent urgent skin biopsies of two lesions on her buttock and thigh. No organisms were seen on Gram stain. The patient's skin biopsy revealed extensive hyperorthokeratosis, minimal parakeratosis, hypergranulosis, and lichenoid interface dermatitis in the irregularly acanthotic epidermis supporting diagnosis of fixed drug eruption. Following a multidisciplinary discussion, the patient was diagnosed with baboon syndrome or symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) associated with Tamoxifen. RESULTS: Hence, Tamoxifen was immediately discontinued and treated with oral steroid along with topical agents. She showed improvement of clinical abnormalities within days after discontinuation of Tamoxifen. CONCLUSIONS: Given the widespread use of Tamoxifen in the management of patients with breast cancer, it is important that healthcare professionals monitor for rare, however clinically significant, and potentially life‐threatening dermatological manifestations of Tamoxifen use, such as baboon syndrome. John Wiley and Sons Inc. 2020-12-13 2021-08 /pmc/articles/PMC8451808/ /pubmed/33253493 http://dx.doi.org/10.1111/jocd.13863 Text en © 2020 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Dermatologic Surgery Articles
Mofarrah, Ramin
Mofarrah, Ramina
Kränke, Birger
Rahmani, Maziar
Jahani Amiri, Kousar
Ghasemi, Maryam
Jallab, Naghmeh
Ghobadiaski, Sueshianth
Rahmani, Nazgol
Hashemi, Narges
First report of tamoxifen‐induced baboon syndrome
title First report of tamoxifen‐induced baboon syndrome
title_full First report of tamoxifen‐induced baboon syndrome
title_fullStr First report of tamoxifen‐induced baboon syndrome
title_full_unstemmed First report of tamoxifen‐induced baboon syndrome
title_short First report of tamoxifen‐induced baboon syndrome
title_sort first report of tamoxifen‐induced baboon syndrome
topic Dermatologic Surgery Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451808/
https://www.ncbi.nlm.nih.gov/pubmed/33253493
http://dx.doi.org/10.1111/jocd.13863
work_keys_str_mv AT mofarrahramin firstreportoftamoxifeninducedbaboonsyndrome
AT mofarrahramina firstreportoftamoxifeninducedbaboonsyndrome
AT krankebirger firstreportoftamoxifeninducedbaboonsyndrome
AT rahmanimaziar firstreportoftamoxifeninducedbaboonsyndrome
AT jahaniamirikousar firstreportoftamoxifeninducedbaboonsyndrome
AT ghasemimaryam firstreportoftamoxifeninducedbaboonsyndrome
AT jallabnaghmeh firstreportoftamoxifeninducedbaboonsyndrome
AT ghobadiaskisueshianth firstreportoftamoxifeninducedbaboonsyndrome
AT rahmaninazgol firstreportoftamoxifeninducedbaboonsyndrome
AT hasheminarges firstreportoftamoxifeninducedbaboonsyndrome